Hims & Hers Health’s Q2 2026: A Doctor-Led AI Push Keeps Growth Running, With an Eye on 2030 Targets

Overview: A strong quarter, a longer runway

Hims & Hers Health, Inc. reported second-quarter results for 2026 that read like a growth memo in search of a longer-term profitability chapter. The company posted revenue of approximately $753 million, a 38% year-over-year rise, while subscribers climbed to nearly 2.9 million, up 19% from the prior year. In the language of earnings disclosures, the top line milestone lands alongside a narrative shift: the company is leaning into a global, doctor-led AI-enhanced care platform as the engine for both scale and pricing power.

Management raised the full-year 2026 revenue outlook to a range of $3.1 billion to $3.3 billion and lifted the Adjusted EBITDA target to a range of $275 million to $325 million. The framing is deliberate: growth is re-accelerating, and the path to profitability is being recalibrated upward with the help of AI-enabled care delivery and technology-driven efficiencies.

“Hims & Hers is delivering a world-class health experience at a global scale and a reasonable price for the nearly 3 million people who rely on us for access to care,” said Andrew Dudum, co-founder and CEO. “We’re proving, quarter after quarter, that helping people feel great and delivering strong results aren’t mutually exclusive.”

CFO Yemi Okupe echoed the theme, highlighting a 16% YoY domestic revenue uplift and a more-than-17-fold expansion in the international business, aided by the June close of the Eucalyptus acquisition. The forward-looking tone is clear: the company sees domestic momentum continuing in the second half of 2026, aided by ongoing investments in AI and technology that it believes will translate into broader reach and improved cost structure.

Key numbers at a glance

• Revenue: ~ $753 million for Q2 2026 (up 38% YoY)
• Subscribers: ~ 2.9 million (up ~19% YoY)
• 2026 revenue guidance: $3.1 billion to $3.3 billion
• 2026 Adjusted EBITDA guidance: $275 million to $325 million
• Domestic revenue growth: ~16% YoY
• International growth: > 17x YoY, aided by Eucalyptus acquisition (June close)
• Longer-term targets: >= $6.5 billion in revenue and >= $1.3 billion in Adjusted EBITDA by 2030

What this implies for HIMS and its sector peers

The quarter reinforces a growth narrative anchored in a blended model: a broad health-and-wellness platform, a direct-to-consumer cadence, and a push into international markets where the base is lighter but the runway is long. The inclusion of an AI-driven, doctor-led clinical engine is not just a talking point; it is pitched as the lever for higher quality care at a lower marginal cost, which in turn should support more aggressive subscriber expansion and revenue per user over time.

The absence of a disclosed EPS figure in the excerpt leaves a gap for the EPS consensus conversation, but the company’s emphasis on revenue and EBITDA guidance signals a shift from “growth at any cost” toward a more measured profitability trajectory. If the market is hoping for an explicit earnings surprise versus consensus, the headline numbers (revenue and EBITDA) are the headline act, with EPS likely to be a factor in subsequent releases as the company integrates the Eucalyptus acquisition and scales its AI stack.

The Eucalyptus deal appears to be the fulcrum of the international story. A >17-fold step-up in international revenue implies a lot of moving parts—pricing, local regulatory nuance, and the installation of the doctor-led AI care engine in a variety of markets. If the integration proceeds smoothly, the company could generate meaningful operating leverage as international customers mature and as cross-sell opportunities unfold. But if integration friction appears or if localization costs creep higher than anticipated, the street will re-price the margin and the growth trajectory accordingly.

From a sector perspective, HIMS’s approach reflects a broader trend: consumer health platforms trying to fuse high-touch care with scalable technology. The question for peers becomes: can AI-enabled care deliver sustainable margin expansion, or will the unit economics remain a function of marketing spend and care access expansion? The answer will hinge on how well they convert rapidly growing access into durable health outcomes, and how effectively they manage cost structure in a data-heavy, regulated business.

Risks and lines of caution

The durability of the 2026 acceleration depends on several moving parts: how well the AI engine actually translates into care efficiency and patient retention, whether cost of growth moderates as the subscriber base scales, and how regulatory and privacy considerations shape product and cross-border expansion. The guidance implies confidence in the near-term trajectory, but investors will look for quarterly proof that the international push and the AI-enabled model produce margin expansion, not just top-line growth.

Takeaways for investors and the industry

In short, the Q2 showing reinforces a category thesis: a global, AI-augmented care platform with a broad subscriber base can sustain rapid revenue growth while edging toward profitability. The company’s 2030 targets—$6.5 billion in revenue and $1.3 billion in Adjusted EBITDA—signal a long-range plan that moves beyond the next few earnings seasons and invites scrutiny on how much of the run-rate acceleration is real and how much is the result of favorable comp and acquisitions.

For peers, the lesson is twofold: first, AI-enabled care delivery is not a vanity project; it’s presented as a core driver of unit economics if the cost structure can be meaningfully improved. Second, international expansion remains a high-variance, high-reward frontier—great upside if integration and localization costs stay controlled; material risk if execution lags.

Bottom line

Hims & Hers Health is painting a picture of sustained growth anchored by a broadened international footprint and a technology stack designed to compress care costs. The headline numbers—revenue near $753 million, 38% YoY growth, 2.9 million subscribers, and raised 2026 guidance—keep the stock in the conversation. The real test will be whether EPS results and earnings surprise metrics start to align with a path to steady revenue forecast improvement and robust EPS consensus over the next several quarters.

If the market buys into the narrative that AI-enabled care can meaningfully lift margins while expanding the addressable market, HIMS could become a case study in how direct-to-consumer health platforms scale without sacrificing care quality. If not, the same AI-driven upside will be a talking point, but investors will demand a clearer, quarterly demonstration of durable profitability.

Either way, the company’s focus on a doctor-led AI engine, ongoing acquisitions, and the prospect of rising international contribution makes for an interesting watch list for sector peers and incumbents hungry for a similar growth-to-margin transition.